Restrictive Lung diseases Flashcards

1
Q

Different interstitial lung diseases?

A
  • idiopathic pulmonary fibrosis
  • sarcoidosis
  • radiation induced injury
  • pneumoconiosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What does restriction in lung disorders always mean for the FVC?

A
  • it always means a decrease in lung volume (FVC)
  • total lung capacity if measured is significantly reduced
  • total lung capacity = FVC + RV
  • FEV1 may be reduced
  • so ratio of FEV1 to FVC is normal or increased
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the cause of asbestosis?

A
  • inhalation of asbestos fibers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 2 categories of asbestosis fibers?

A
  • chrysotile and amphibole

- chrysotile is less toxic and accounts for 90% of asbestos use in the U.S.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the disease manifestations of asbestosis?

A
  • characterized by slowly progressive (years), diffuse pulmonary fibrosis
  • spectrum: asbestosis, pleural dz, and malignancies
  • malignancies: non-small cell carcinoma of the lungs - malignant mesothelioma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the pathogenesis of asbestosis?

A
  • direct toxic effect of the fibers on pulmonary cells and release of mediators from inflammatory cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the clinical findings of asbestosis?

A
  • most pts are asymptomatic for 20-30 years after initial exposure:
    dyspnea on exertion
    progresses to fine bibasilar and expiratory crackles and clubbing
  • if cough, sputum production or wheezing are present more likely secondary to smoking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dx process of asbestosis?

A
  • PFTs: reduced lung volumes: VC and TLC
    decreased pulmonary compliance, and absence of airflow obstruction (normal ratio of FEV1 to FVC)
  • radiographs: begins in lower lung zones with small parenchymal opacities with a multinodular or reticular pattern
    often associated pleural abnormalities, shaggy heart and ground glass appearance
    and honeycombing and upper lobe involvement late stage disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pathogenesis of Bronchiolitis Obliterans?

A
  • chronic airway rejection in lung transplant pts due to:
    episodes of acute rejection, primary graft dysfunction, CMV pneumonitis, noncompliance with immunosuppressive meds and lymphocyte bronchitis or bronchiolitis
  • can develop farther out from transplant: 5 years after lung transplant 45% of recipients develop BO, this is often a slow, relentless progression
  • the mortality rate is 25-56%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the presentation of bronchiolitis obliterans?

A
  • usually indolent sxs similar to URI
  • exertional dyspnea and decline in spirometry
  • initially radiographs and exam only help exclude other illnesses
  • advanced stages: see bronchioectasis with obstruction and hyperinflation, often colonized with pseudomonas
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Dx of bronchiolitis obliterans?

A
  • requires transbronchial biopsies with BAL:
    usually made on a pt who presents with declining spirometry without an acute illness
  • yield of transbronchial biopsies can be variable
  • need a good bronchoscopy technique and adequate bronchio-alveolar lavage
  • rule out infection!!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tx of BO?

A
  • changing anti-immune meds
  • photopheresis
  • retransplantation
  • prevention: make sure pts are taking immunosuppression drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is hypersensitivity pneumonitis also known as?

A
  • extrinsic allergic alveolitis
  • it represents an immunologic reaction to an inhaled agent: usually an organic antigen, and occurs within the pulmonary parenchyma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the inciting agents of hypersensitivity pneumonitis?

A
  • agricultural dusts
  • bioaerosols
  • reactive chemical species
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Epidemiology of HP?

A
  • ** remains largely unknown and variable: farmer’s lung affects 0.4-7% of the farming population with a prevalence of 420-3000 per 100000 persons
  • prevalence of HP in bird fanciers ranges from 20-20000 affected persons per 100000
  • cigarette smoking is associated with a decreased risk of HP
  • individuals who develop HP have genetic factors that play a role
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

List of HP etiologic agents?

A
  • farming, vegetable and dairy cattle workers
  • ventilation and water related contamination
  • bird and poultry handling (exposure to down)
  • veterinary work and animal handling
  • grain and flour processing and loading (grain can become colonized with microorganisms and insects, grain is easily aerosolized so exposure to antigens can occur easily
  • lumbar milling, construction, wood stripping: mold exposure
  • plastic manufacturing
  • painting
  • electronics industry
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Presentation of acute HP?

A
  • may follow heavy exposure to antigen
  • may be confused with viral or bacterial infection
  • abrupt onset (4-6 hrs after exposure) of:
    fever and chills
    nausea
    chest tightness and dyspnea without wheezing
  • PE: tachypnea and diffuse fine rales
  • tx: removal from antigen, sxs subside in 12 hours to several days, disease may recur with re-exposure
  • labs: want to order CBC, and white count
    CXR: may show a micronodular, interstitial pattern, frequently normal, sometimes do HRCT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Subacute of intermittent HP?

A
  • low level exposure over time: farmers lung or chemical workers
  • gradual development of productive cough, dyspnea, fatigue, anorexia, and wt loss
  • PE: tachypnea, diffuse rales
  • lab: lymphocytosis on BAL, mild hypoxemia
  • PFTs: restriction pattern or mixed restriction/obstruction pattern
  • x-rays: normal or reticular opacities in middle and upper lung zones, acinar nodules
  • Tx: removal from antigen and glucocorticosteroids, takes weeks to months to resolve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Presentation of chronic progressive HP?

A
  • generally no report of acute episodes
  • insidious onset of cough, dyspnea, fatigue and wt loss
  • PE: digital clubbing may be seen, diff from idiopathic pulmonary fibrosis is difficult
  • lab: lymphocytosis, also neutrophilia or eosinophilia on BAL
  • PFTs: restrictive, obstructive often seen with it, resting and exertional hypoxemia
  • x rays: fibrotic changes, loss of lung volume, emphysema pattern changes (perm. changes)
20
Q

DDx of HP?

A
  • inhalation fever
  • organic dust toxic syndrome
  • chronic bronchitis
  • asthma
  • chronic airflow limitation
21
Q

How do you dx HP?

A
  • high index of suspicion
  • careful review of pts occupational, avocational, and domestic exposures
  • a normal CXR doesn’t rule it out
  • inhalation challenge by re-exposure
  • HRCT and BAL (intermittent or chronic)
22
Q

Tx of HP?

A
  • antigen avoidance

- glucocorticoids used to accelerate initial recovery, however the long term outcome is relatively unchanged

23
Q

Prevention of HP?

A
  • reduction of antigenic burden (wetting compost)
  • design facilities: maintain humidity less than 60%, avoid having stagnant water or carpet that is likely to get moist
  • maintenance: routinely inspect all heating, ventilation, an air conditioning equipment that it is clean and water is drained daily from humidifiers and vaporizers
  • protective devices: masks, and filters
24
Q

What is interstitial lung disease?

A
  • diffuse parenchymal lung disease
  • collectively referred to as the ILDs
  • a heterogeneous group of disorders that are classified together becuase of similar clinical, x-ray, physiologic or pathologic manifestations
  • most of these disorders are associated with extensive alteration of alveolar and airway architecture
25
Q

Presentation of ILD?

A
  • 50% idiopathic (idiopathic pulmonay fibrosis)
  • clinically presents with progressive exertional dyspnea and nonproductive cough
  • presents on x-ray with haziness progress to nodules then linear opacities
  • prognosis: usually die of respiratory failure within 3-6 years once x-ray changes
26
Q

Acute restricitve lung disease?

A
  • acute idiopathic pneumonia
  • eosinophilic pneumonia
  • hypersensitivity pneumonia
  • bronchiolitis obliterans organizing pneumonia
27
Q

Subacute restrictive lung disease?

A
  • sarcoidosis
  • some drug induced ILDs
  • alveolar hemorrhage syndromes
  • conntective tissue disease (SLE)
28
Q

Chronic restrictive lung disease?

A
  • idiopathic pulmonary fibrosis
  • sarcoidosis
  • pulmonary langerhans cell histiocytosis
29
Q

What is Idiopathic pulmonary firbosis? Who does it affect? Rfs?

A
  • chronic, relentlessly progressive fibrotic disorder of the lower respiratory tract
  • affects adults older than 40
  • precise factors that initiate and maintain inflammatory and fibrotic responses in IPF are unknown
  • RFs: infections, enviro pollutants, chronic aspiration, and drugs
30
Q

IPF pathogenesis?

A
  • early in IPF alveolitis is dominated by inflammatory cells including:
    alveolar macrophages - secrete proinflammatory and profibrotic cytokines which affect mesenchymal cell proliferation and promote collagen depositions
  • neutrophils
  • eosinophils
  • lymphocytes
  • increased numbers of basophils and mast cells
31
Q

Presentation of IPF? Dx process?

A
  • dyspnea on exertion
  • persistent nonproductive cough
  • abnormal CXR
    Dx:
    routine blood tests - including serologic studies and autoimmune testing to r/o other diseases, radiographs, HRCT, PFTs: restrictive pattern, BAL: looking for neutrophils, lymphocytosis - indicates HP
32
Q

Tx of IPF?

A
  • no randomized placebo-controlled trials show that tx is beneficial
  • prognosis of disease is dismal
  • uncertainity remains about the following:
    which pts should be treated?
    when should therapy be started?
    what is the best therapy?
    how should the disease course and response to tx be monitored?
    meds used: glucocorticoids
    immunosuppressives: azathiprine, cyclophosphamide, methotrexate
    antioxidants: acetylcysteine
33
Q

What is sarcoidosis?

A
  • a multisystem granulomatous disorder of unknown etiology that affects people worldwide
  • characterized pathologically by the presence of noncaseasting granulomas in involved organs
  • typically affects young adults, initially presents with one or more of the following:
    bilateral hilar lymphadenopathy
    pulmonary reticular opacities, skin, joint or eye lesions
34
Q

What % of pts with sarcoidosis have lung involvement?

A
  • over 90% of pts

- staged according to CXR

35
Q

Presentaion of sarcoidosis?

A
  • dyspnea
  • cough (nonproductive)
  • chest pain
36
Q

Tx of pulmonary sarcoidosis?

A
  • large number of pts undergo spontaneous remission or have benign clinical course
  • no easy way to assess dz activity and severity, so predicting clinical course and prognosis of disease is difficult
  • marked variability in presentation and clinical course make it difficult to develop tx guidelines
  • cause of dz is unknown so no specific tx exists
37
Q

Indications for tx of pulmonary sarcoidosis?

A
  • worsening pulmonary sx: cough, dyspnea, chest pain, or discomfort, and hemoptysis
  • deteriorating lung fxn
  • progressive radiographic changes
  • tx with glucocorticoids: daily, if improvement slowly taper, if reactivation of disease increase to last effective dose and tx for 3-6 months, some pts require maintenance dose
38
Q

What is drug induced pulmonary disease?

A
  • eosinophilic pneumonias:
    present 2-10 days after drug started, sxs: dry cough, fever, chills, and dyspnea, radiograph: eosinophilic pleural effusion + patchy or diffuse pulmonary infiltrates
39
Q

What drugs are associated with drug induced pulmonary disease (eosinophilic pneumonia)?

A
  • nitrofurantoin
  • sulfonamides
  • penicillin
  • thiazides
  • tricyclic antidepressants
  • hydralazine
  • isonaizid
  • gold salts
    tx: withdrawing use of drug
40
Q

What are the 2 types of radiation-induced lung injury?

A
  • radiation pneumonitis
  • radiation fibrosis (long term)
  • both are seen in pts who have undergone thoracic radiation for breast, lung, esophageal, stomach cancer and lymphoma
  • radiation induced damage dose is limiting factor
41
Q

Pathogenesis of radiation induced lung injury?

A
  • ionizing radiation localized release of sufficient energy to break strong chemical bonds and generate highly reactive free radical species
  • radiation induced lung injury results from the combo of direct cytotoxicity upon normal lung tissue and the development of fibrosis triggered by radiation induced cellular signal transduction
  • cytotoxic effect is largely due to DNA damage that causes clonagenic death in normal lung epithelial cells
42
Q

What factors affect the development of radiation induced lung disease?

A
  • method of irradiation
  • volume of lung irradiated
  • dosage of radiation
  • time dose factor
  • concurrent chemo
  • induction chemo
43
Q

Clinical manifestations of radiation induced lung injury? Findings on PE?

A
  • early nonproductive cough
  • dyspnea on exertion or inability to take a deep breath
  • low grade fever
  • chest pain: pleuritic, substernal
  • malaise and wt loss may be seen (cancer or radiation caused?)
  • PEs:
    fine crackles or pleural rub, sometimes normal
    **pleural friction rub
    dullness to percussion
    tachypnea, cyanosis or signs of pulm. HTN (severe)
44
Q

Chest imaging for DDX? findings on CXR?

A
- need to distinguish from other pulmonary dz:
infection
lymphagitic or direct extension of tumor
drug induced pneumonitis
hemorrhage
cardiogenic edema

CXR: may be normal, patchy alveolar filling defects, straight line effect, not conforming to anatomical units but to confines of radiation port is dx (straight lines in radiation field)
- small pleural effusions

45
Q

Tx of radiation induced lung injury?

A
  • corticosteroids
  • inhibition of collagen synthesis
  • stop radiation
46
Q

What is pneumoconiosis?

A
  • nonneoplastic reaction of lung to inhaled mineral or organic dust
  • examples: silicosis, coal workers, can be complicated by infection and smoking
47
Q

Presentation of coal worker’s pneumoconiosis?

A
  • asymptomatic
  • may cause chronic bronchitis and COPD so is then known as industrial bronchitis and is compensable
  • radiographically: small opacities can progress to larger opacities and fibrosis